Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Key to prevent the next major pandemic.

Wellcome 21 [Wellcome is a global charitable foundation that funds research in the areas of climate change, infectious disease, and mental health. Julia Gillard is the Chair of the Board of Governors and served as Australia’s Deputy Prime Minister and Prime Minister (2007-2013). “How to prevent another major pandemic,” https://wellcome.org/news/how-prevent-another-major-pandemic#.] cgarland

Provide a sound financial footing for pandemic preparedness and response The problem Global solutions need collective investment. Since the Covid-19 pandemic started, we have seen increased investment in research, manufacturing and distribution of Covid-19 tests, treatments and vaccines. Paradoxically, we’ve not seen the same increase in Research and Development (R&D) for diseases that are at risk of becoming the next pandemic. Continuing to fight the Covid-19 pandemic doesn’t lower the chances of another health threat. The health and economic benefit of investing in these tools now and for future pandemic diseases has never been clearer. But major gaps in the world’s capabilities persist, such as in globally networked surveillance and research to prevent and detect emerging or escalating infectious diseases. The mechanisms to mobilise global funding for these crucial tools are limited, leaving every country in our interconnected world vulnerable. The solution We need governments to build collective financing mechanisms to transform the world’s ability to prepare for and respond to pandemic threats. Governments’ contributions to new financing mechanisms, such as , must be in proportion to their ability to pay. And this money must be in addition to overseas development assistance, so that it doesn’t compete with other critical health and development priorities. 3. Invest in the gaps in infrastructure to monitor and respond to threats The problem Covid-19 has shown us the blind spots in the world’s ability to detect, track and respond to emerging viruses. The world did not have the right infrastructure in place to respond to Covid-19 and so it could not act at speed to contain the initial outbreak. To prevent pandemics, we need to invest in three areas: surveillance, manufacturing and co-ordinated research and development. The solution Surveillance Finding new pathogens quickly is critical to containing them. There are too many global ‘dark spots’ where new viruses cannot be identified – but building locally-owned, internationally-connected will ensure we can spot potential dangers before they become a global problem. This network must work with local communities and be used between outbreaks to tackle other infectious diseases and urgent global threats. With sustainable, long-term investment this network can inform powerful regional and international responses to all infectious diseases rapidly and efficiently. Manufacturing Throughout Covid-19, we have seen what happens when vaccines and treatments are produced in a small number of countries. High-income countries buy-up the global supply, leaving the virus to thrive elsewhere. Access to these tools is a question of both supply and delivery. We need to increase regional manufacturing capacity. This will ensure more people will have access to treatments and vaccines. While efforts to diversify manufacturing capacity could take several months to have a positive impact on Covid-19 vaccine supply, increasing regional manufacturing capacity will have long term benefits for future pandemics globally, while ensuring local needs are met. Research and Development (R&D) At the start of the Covid-19 pandemic, very little was known about the virus, even less how to diagnose, treat and prevent it. Thankfully, scientists could build on existing research on other coronaviruses, such as vaccines for MERS and new mRNA technology. . Next time, the world may not be so lucky. , where failures to continue key areas of research between outbreaks led to a delay in the development of usable diagnostics, treatments and vaccines when the next outbreak hit. There are still no WHO-approved diagnostic tests for six out of the . We must be prepared for all plausible scenarios – and this means more investment in R&D. We need a system that leads and supports equitable and collaborative R&D programmes to deliver a full range of countermeasures, such as diagnostics, therapeutics, and vaccines, available to respond to a pandemic. It would need to work with industry as well as global health organisations and have equitable access to its products at its heart. And will only be successful if leaders commit to transparency and openness in sharing the information they collect with the world.

Sign in to recut, update, or save this card.